HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Development of a keratoacanthoma after topical photodynamic therapy with 5-aminolevulinic acid.

Abstract
Since its FDA approval in 1999, photodynamic therapy (PDT) with topical 5-aminolevulinic acid has become an increasingly popular modality for the treatment of actinic keratosis (AKs). It is hoped that in addition to improving clinical signs and symptoms of AKs, PDT might prevent the development of skin cancer. We present a case of a patient developing a keratoacanthoma immediately following PDT for AKs.
AuthorsElena Maydan, Pavan K Nootheti, Mitchel P Goldman
JournalJournal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 5 Issue 8 Pg. 804-6 (Sep 2006) ISSN: 1545-9616 [Print] United States
PMID16989196 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Photosensitizing Agents
  • Aminolevulinic Acid
Topics
  • Administration, Topical
  • Aminolevulinic Acid (adverse effects)
  • Humans
  • Keratoacanthoma (chemically induced)
  • Keratosis (drug therapy)
  • Male
  • Middle Aged
  • Photochemotherapy (adverse effects)
  • Photosensitizing Agents (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: